Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
203 articles by Michael Gibney
-
Regeneron takes the long-haul approach to oncology, stumbles and all
Oct. 10, 2024 -
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
Oct. 3, 2024 -
Top pharma and biotech conferences 2025
Oct. 1, 2024 -
Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Sept. 26, 2024 -
Want better cancer treatments? Make biopharma more like Silicon Valley
Sept. 24, 2024 -
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
Sept. 19, 2024 -
How a radiopharma up-and-comer builds momentum in a surging space
Sept. 17, 2024 -
How Lilly’s sustainability goals come face to face with massive growth
Sept. 12, 2024 -
A new way of determining a drug’s value — with health equity in mind
Sept. 10, 2024 -
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
Sept. 4, 2024 -
Their Alzheimer’s treatment worked — but shares fell anyway
Aug. 29, 2024 -
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
Aug. 27, 2024 -
23andMe inches closer to cancer immunotherapy, guided by its genetic database
Aug. 20, 2024 -
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
Aug. 15, 2024 -
A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
Aug. 13, 2024 -
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
Aug. 8, 2024 -
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
Aug. 6, 2024 -
7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run
July 30, 2024 -
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
July 18, 2024 -
Has pharma emerged from the ‘age of uncertainty’?
July 16, 2024 -
As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat
July 11, 2024 -
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
July 9, 2024 -
How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
July 2, 2024 -
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
June 27, 2024 -
Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?
June 25, 2024